Open AccessLower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
Author(s) -
Kent C. Johnson,
Xin Niu,
David V. Glidden,
José CastilloMancilla,
Jenna Yager,
Samantha MaWhinney,
Mary Morrow,
Hideaki Okochi,
Tim R. Cressey,
Paul K. Drain,
Monica Gandhi,
Peter L. Anderson,
Matthew A Spinelli
Publication year - 2021
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofab200
Subject(s) - tenofovir alafenamide , medicine , tenofovir , urine , cobicistat , human immunodeficiency virus (hiv) , antiretroviral therapy , virology , viral load
From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.